Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04925284 · ClinicalTrials.gov registry record · Phase 1
Study of XB002 in Subjects With Solid Tumors (JEWEL-101)
A Phase 1 study of Non-Small Cell Lung Cancer and Pancreatic Cancer, sponsored by Exelixis.
- Completed
- Registry status
- Phase 1
- Development phase
- 269
- Enrollment target
- 20
- Study locations
NCT04925284: Completed Phase 1 study of Non-Small Cell Lung Cancer and Pancreatic Cancer, sponsored by Exelixis.
NCT04925284 is a Phase 1 study of Non-Small Cell Lung Cancer and Pancreatic Cancer that has completed, run by Exelixis. The registered enrollment target is 269 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (59% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04925284, a Phase 1 study of Non-Small Cell Lung Cancer and Pancreatic Cancer, has completed, sponsored by Exelixis.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 269 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 1, open-label, multicenter, dose-escalation and expansion study evaluating the safety, tolerability, PK, pharmacodynamics, and clinical antitumor activity of XB002 administered IV q3w alone and in combination with nivolumab or bevacizumab to subjects with advanced solid tumors.
Primary Outcome
To determine the MTD and/or RD for further evaluation of IV administration of XB002 alone and in combination therapy in subjects with advanced malignancies
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Nivolumab
- DRUG XB002
Study Locations (20)
California
- Exelixis Clinical Site#59 - Fountain Valley
- Exelixis Clinical Site #21 - Los Angeles
- Exelixis Clinical Site #26 - Los Angeles
Arizona
- Exelixis Clinical Site #20 - Tucson
- Exelixis Clinical Site#95 - Tucson
Maryland
- Exelixis Clinical Site #6 - Baltimore
- Exelixis Clinical Site #18 - Columbia
Michigan
- Exelixis Clinical Site #19 - Detroit
- Exelixis Clinical Site #10 - Detroit
New Jersey
- Exelixis Clinical Site #8 - East Brunswick
- Exelixis Clinical Site #7 - New Brunswick
Alabama
- Exelixis Clinical Site #48 - Birmingham
Arkansas
- Exelixis Clinical Site#58 - Little Rock
Connecticut
- Exelixis Clinical Site #16 - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 269 participants |
| Start Date | 2021-06-07 |
| Est. Completion | 2025-03-10 |
| Phase | Phase 1 |
What the finished NCT04925284 record still lists
NCT04925284 is an interventional study that assigns participants to a tested intervention. The registered 269 participants enrollment target is mid-sized for trials with a published cap, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (59% lower).
The record links to 10 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 3 interventions - of which Bevacizumab is the first listed.
NCT04925284 names 20 study sites across 14 states, led by California, Arizona, Maryland.
Frequently Asked Questions
What is clinical trial NCT04925284 about?
NCT04925284 is a clinical study titled "Study of XB002 in Subjects With Solid Tumors (JEWEL-101)". This is a Phase 1, open-label, multicenter, dose-escalation and expansion study evaluating the safety, tolerability, PK, pharmacodynamics, and clinical antitumor activity of XB002 administered IV q3w alone and in combination with nivolumab or bevacizumab to subjects with advanced solid tumors.
What is the current status of trial NCT04925284?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 269 participants. The study started on 2021-06-07. Estimated completion is 2025-03-10.
What conditions does trial NCT04925284 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Pancreatic Cancer, Endometrial Cancer, Cervical Cancer, Triple Negative Breast Cancer.
What interventions are being tested in trial NCT04925284?
The interventions under investigation include: Bevacizumab (DRUG), Nivolumab (DRUG), XB002 (DRUG).
Who is sponsoring clinical trial NCT04925284?
This trial is sponsored by Exelixis, which has 48 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04925284 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04925284's enrollment target sits among peer trials
269 141st of 454 higher than 314 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04802291 · 269 participants · NA
HomeStyles-2: Shaping HOME Environments and LifeSTYLES to Prevent Childhood Obesity
- NCT06500455 · 269 participants · Phase 3
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
- NCT06630676 · 269 participants · NA
The Ability of Chronic Pain Patients to Self-diagnose Their Chief Source of Low Back Pain
- NCT00801489 · 270 participants · Phase 2
Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI